United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - methotrexate sodium (unii: 3ig1e710zn) (methotrexate - unii:yl5fz2y5u1) - methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. in acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. methotrexate is also indicated in the treatment of meningeal leukemia. methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous t cell lymphoma), and lung cancer, particularly squamous cell and small cell types. methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-hodgkin's lymphomas. methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - methotrexate, quantity: 25 mg/ml - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - methotrexate injection usp belongs to a group of medicines known as anti-metabolites. it is used in high doses to treat certain types of cancers, including breast cancer, non-hodgkin's lymphoma and leukemia. at lower doses, it may be used to treat psoriasis and severe rheumatoid arthritis.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - aciclovir 25 mg/ml;   - solution for injection - 25 mg/ml - active: aciclovir 25 mg/ml   excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection

Ireland - English - HPRA (Health Products Regulatory Authority)

strides arcolab international limited - methotrexate - solution for inj/inf - 25 mg/ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - methotrexate sodium - solution for injection - 25mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - methotrexate sodium - solution for injection - 25mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - methotrexate sodium - solution for injection - 25mg/1ml

United States - English - NLM (National Library of Medicine)

accord healthcare, inc. - methotrexate (unii: yl5fz2y5u1) (methotrexate - unii:yl5fz2y5u1) - methotrexate 25 mg in 1 ml - methotrexate injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (all) as part of a combination chemotherapy regimen. methotrexate injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients. methotrexate injection is indicated for the treatment of adults and pediatric patients with non-hodgkin lymphoma. methotrexate injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. methotrexate injection is indicated for the treatment of adults with breast cancer as part of a combination chemotherapy regimen. methotrexate injection is indicated for the treatment of adults with squamous cell carcinoma of the head and neck as a single-agent. methotrexate injection is indicated for the treatment of adults with gestational trophoblastic neoplasia (gtn) as part of a combination chemotherapy regimen. methotrexate injection is indicated for

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - solution for injection - methotrexate 25 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - solution for injection - methotrexate 25 mg/ml - antineoplastic agents